Cyclosaligenyl-2',3'-didehydro-2',3'-dideoxythymidine monophosphate: efficient intracellular delivery of d4TMP. 2000

J Balzarini, and S Aquaro, and T Knispel, and C Rampazzo, and V Bianchi, and C F Perno, and E De Clercq, and C Meier
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium. jan.balzarini@rega.kuleuven.ac.be

Cyclosaligenyl-2',3'-didehydro-2', 3'-dideoxythymidine-5'-monophosphate (cycloSal-d4TMP) is a potent and selective inhibitor of human immunodeficiency virus replication in cell culture and differs from other nucleotide prodrug approaches in that it is designed to selectively deliver the nucleotide 5'-monophosphate by a controlled, chemically induced hydrolysis. Its antiviral efficacy in cell culture is at least as good as, if not superior to, that of d4T. CycloSal-d4TMP was found to lead to the efficient intracellular release of d4TMP in a variety of cell lines, including both wild-type CEM and thymidine kinase-deficient CEM/TK(-) cells. Under similar experimental conditions, exposure of CEM/TK(-) cells to d4T failed to result in significant d4TTP levels. The intracellular conversion of cycloSal-d4TMP proved to be both time and dose dependent. The half-life of d4TTP generated intracellularly from d4T- or cycloSal-d4TMP-treated CEM cells was approximately 3.5 h, and the intracellular ratios of d4TTP/d4TMP in cells exposed to cycloSal-d4TMP gradually increased from 1 to 3.4 upon prolonged incubation. Radiolabeled cycloSal-d4TMP could be separated as its two R(p) and S(p) diastereomers on high-performance liquid chromatography. The R(p) diastereomer of cycloSal-d4TMP was 3- to 7-fold more efficient in releasing d4TMP and generating d4TTP than the S(p) cycloSal-d4TMP diastereomer. This correlated well with the 5-fold more pronounced antiviral activity of the R(p) diastereomer versus the S(p) diastereomer. d4TMP is a poor substrate for the cytosolic 5'(3')-deoxyribonucleotidase (V(max)/K(m) for d4TMP: 0.08 of V(max)/K(m) for dTMP) and is only slowly hydrolyzed to d4T. This contributes to the efficient conversion of the prodrug of d4TTP.

UI MeSH Term Description Entries
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D003470 Culture Media Any liquid or solid preparation made specifically for the growth, storage, or transport of microorganisms or other types of cells. The variety of media that exist allow for the culturing of specific microorganisms and cell types, such as differential media, selective media, test media, and defined media. Solid media consist of liquid media that have been solidified with an agent such as AGAR or GELATIN. Media, Culture
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D013936 Thymidine A nucleoside in which THYMINE is linked to DEOXYRIBOSE. 2'-Deoxythymidine,Deoxythymidine,2' Deoxythymidine
D013937 Thymidine Kinase An enzyme that catalyzes the conversion of ATP and thymidine to ADP and thymidine 5'-phosphate. Deoxyuridine can also act as an acceptor and dGTP as a donor. (From Enzyme Nomenclature, 1992) EC 2.7.1.21. Deoxythymidine Kinase,Deoxypyrimidine Kinase,Kinase, Deoxypyrimidine,Kinase, Deoxythymidine,Kinase, Thymidine
D013938 Thymidine Monophosphate 5-Thymidylic acid. A thymine nucleotide containing one phosphate group esterified to the deoxyribose moiety. DTMP,TMP,Thymidylic Acid,Deoxythymidylate,Thymidylic Acids,Acid, Thymidylic,Acids, Thymidylic,Monophosphate, Thymidine

Related Publications

J Balzarini, and S Aquaro, and T Knispel, and C Rampazzo, and V Bianchi, and C F Perno, and E De Clercq, and C Meier
November 1996, Molecular pharmacology,
J Balzarini, and S Aquaro, and T Knispel, and C Rampazzo, and V Bianchi, and C F Perno, and E De Clercq, and C Meier
April 1998, Journal of medicinal chemistry,
J Balzarini, and S Aquaro, and T Knispel, and C Rampazzo, and V Bianchi, and C F Perno, and E De Clercq, and C Meier
April 1989, The Journal of biological chemistry,
J Balzarini, and S Aquaro, and T Knispel, and C Rampazzo, and V Bianchi, and C F Perno, and E De Clercq, and C Meier
October 1992, Antiviral research,
J Balzarini, and S Aquaro, and T Knispel, and C Rampazzo, and V Bianchi, and C F Perno, and E De Clercq, and C Meier
August 1997, Antiviral research,
J Balzarini, and S Aquaro, and T Knispel, and C Rampazzo, and V Bianchi, and C F Perno, and E De Clercq, and C Meier
February 1991, Biochemical and biophysical research communications,
J Balzarini, and S Aquaro, and T Knispel, and C Rampazzo, and V Bianchi, and C F Perno, and E De Clercq, and C Meier
September 1995, Journal of medicinal chemistry,
J Balzarini, and S Aquaro, and T Knispel, and C Rampazzo, and V Bianchi, and C F Perno, and E De Clercq, and C Meier
January 1990, Annals of the New York Academy of Sciences,
J Balzarini, and S Aquaro, and T Knispel, and C Rampazzo, and V Bianchi, and C F Perno, and E De Clercq, and C Meier
July 1999, Antiviral research,
J Balzarini, and S Aquaro, and T Knispel, and C Rampazzo, and V Bianchi, and C F Perno, and E De Clercq, and C Meier
April 2011, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!